C12N 2502/1142
Osteoclasts
C12N2502/1142 (Osteoclasts) appears on 9 US grants and 15 published applications in this corpus.
Search patents in C12N- Granted patents
- 9
- Published applications
- 15
- Assignees
- 11
- Inventors
- 18
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 1 | 1 |
| 2016 | 0 | 0 |
| 2017 | 1 | 0 |
| 2018 | 0 | 1 |
| 2019 | 0 | 0 |
| 2020 | 0 | 3 |
| 2021 | 1 | 2 |
| 2022 | 2 | 2 |
| 2023 | 0 | 0 |
| 2024 | 2 | 2 |
| 2025 | 1 | 2 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Biocompatible conditioned cell medium compositions and uses thereof16 Jun 2026US 12,655,384 B2Cellum Biomedical, Inc.
- Osteoporosis model comprising calcium phosphate hydrogel composition and use thereof18 Mar 2025US 12,252,711 B2Medifab Co., Ltd.
- Biocompatible conditioned cell medium compositions and uses thereof21 May 2024US 11,987,806 B2Cellum Biomedical, Inc.
- T regulatory (Treg) cell transplantation in osteogenesis imperfecta (OI)7 May 2024US 11,975,024 B2MUSC Foundation for Research Development
- Pumpless platform for high-throughput dynamic multicellular culture and chemosensitivity evaluation23 Aug 2022US 11,421,194 B2Hackensack Meridian Health Center for Discovery and Innovation
- Osteoporosis model comprising calcium phosphate hydrogel composition and use thereof12 Jun 2025US 2025/0188416 A1Medifab Co., Ltd.
- Compositions and methods for activating nk cells13 Feb 2025US 2025/0049859 A1The Regents of the University of California
- Biocompatible conditioned cell medium compositions and uses thereof24 Oct 2024US 2024/0352406 A1Cellum Biomedical, Inc.
- Compositions and methods for activating nk cells23 May 2024US 2024/0165152 A1The Regents of the University of California
- Biocompatible conditioned cell medium compositions and uses thereof13 Oct 2022US 2022/0325236 A1Cellum Biomedical, Inc.
Most cited
By later US patents